Klacid

Clarithromycin, the active ingredient in Klacid, is a macrolide antibiotic presented as an intravenous solution for intravenous use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, acute exacerbations of chronic bronchitis, skin and soft‑tissue infections, and is used in combination regimens for Helicobacter pylori eradication.\n\nGNH India supplies Klacid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Klacid is a macrolide antibiotic indicated for several bacterial infections affecting the respiratory and skin systems.\n\nCommunity‑acquired pneumonia: effective bacterial clearance improving respiratory function.\nAcute bacterial sinusitis: reduces sinus inflammation and infection.\nAcute exacerbations of chronic bronchitis: shortens duration of symptoms and prevents complications.\nSkin and soft‑tissue infections: eradicates causative bacteria and promotes wound healing.\nHelicobacter pylori eradication (in combination therapy): contributes to bacterial eradication as part of triple therapy.

Common Side Effects:\n- Nausea\n- Diarrhea\n- Abdominal pain\n- Taste disturbance\n- Headache\n- Elevated liver enzymes\n\nSerious or Rare Side Effects:\n- Severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome\n- Hepatic dysfunction including hepatitis\n- QT interval prolongation leading to arrhythmias\n- Clostridioides difficile‑associated diarrhea\n- Neutropenia or eosinophilic pneumonia\n- Myopathy when combined with certain statins

Before initiating therapy, consider the following precautions.\n\nAssess liver function: monitor hepatic enzymes before and during treatment.\nCheck cardiac status: avoid in patients with known QT prolongation.\nReview drug history: caution with concurrent macrolides or strong CYP3A4 substrates.\nPregnancy category B: use only if the anticipated benefit justifies potential risk.\nStore at room temperature: keep in the original container, protect from light and moisture.

Clarithromycin may interact with several medicines; the severity varies.\n\nMajor Interactions (Avoid):\n- Cisapride: risk of serious cardiac arrhythmias.\n- Pimozide: increased plasma levels leading to neurotoxicity.\n- Ergot alkaloids: precipitate ergotism.\n- St. John’s wort: reduces clarithromycin exposure, compromising efficacy.\n\nModerate Interactions (Monitor Closely):\n- Warfarin: may increase INR; monitor coagulation parameters.\n- Theophylline: increased levels may cause toxicity; observe for symptoms.\n- Statins (e.g., simvastatin): heightened risk of myopathy; check CK levels.\n- Carbamazepine: may lower clarithromycin concentrations; assess clinical response.